Anna Zubkiewicz-Zarębska

Dr. Anna Zubkiewicz-Zarębska

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2014 in Advances in Clinical and Experimental Medicine
Verified
Journal Article
Open access
LULidia Usnarska-Zubkiewicz
Lidia Usnarska-Zubkiewicz
JHJadwiga Hołojda
Jadwiga Hołojda
JDJakub Dębski
Jakub Dębski
AZAnna Zubkiewicz-Zarębska
Anna Zubkiewicz-Zarębska
EZEwa Zagocka
Ewa Zagocka
KKKazimierz Kuliczkowski
Kazimierz Kuliczkowski
AL amyloidosis is an acquired systemic disease in which a pathologic amorphous substance produced as a result of abnormal protein metabolism is deposited in the extracellular space of various tissues. The aim of the study was to investigate the relationship between the kappa and lambda serum free light chains (sFLCs) and the development of AL amyloidosis in patients suffering from multiple myeloma (MM). The investigations included 70 MM patients, 40 females and 30 males, aged 28-83 years. In 37 persons, MM was had been diagnosed recently; 33 patients had been undergoing treatment. Amyloidosis was diagnosed in 18 patients (25.7%), including nine females, nine males; six had newly diagnosed disease. Fifteen patients developed kidney failure. The control group consisted of 10 healthy donors. The concentration of sFLC ls were determined using the immunonephelometric method and expressed in mg/L. In 18 MM patients with amyloidosis the concentration of κ sFLCs ranged from 0.3 to 4780 (x = 854.5, SD = 1289), and was significantly higher (p = 0.039) than in the group without amyloidosis, where the range was from 0.3 to 426.0 (x = 68.9, SD = 98.1). The highest concentration of κ sFLCs was observed in the group of five patients with amyloidosis and renal failure. The concentration of λ sFLCs in patients with amyloidosis ranged from 0.5 to 41600 (x = 3035.7, SD = 9735) and was higher than in MM patients without amyloidosis, where it ranged from 0.5 to 834.0 (x = 79.3, SD = 193). In amyloidosis patients, the concentration of λ sFLCs was significantly higher (p = 0.05) in cases of renal failure as compared with the patients with normal renal function. The concentration of sFLCs is a strong indicator of amyloidosis development in MM patients.

1 August 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
UTUrszula Tokarczyk
Urszula Tokarczyk
Krzysztof KaliszewskiKrzysztof Kaliszewski
Krzysztof Kaliszewski
AKAnna Kopszak
Anna Kopszak
ŁNŁukasz Nowak
Łukasz Nowak
KSKarolina Sutkowska-Stępień
Karolina Sutkowska-Stępień
EJEwa Jankowska
Ewa Jankowska
Deviations in laboratory tests assessing liver function in patients with COVID-19 are frequently observed. Their importance and pathogenesis are still debated. In our retrospective study, we analyzed liver-related parameters: aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), gamma-glutamyltransferase (GGT), total bilirubin (TBIL), albumin, comorbidities and other selected potential risk factors in patients admitted with SARS-CoV-2 infection to assess their prognostic value for intensive care unit admission, mechanical ventilation necessity and mortality. We compared the prognostic effectiveness of these parameters separately and in pairs to the neutrophil-to-lymphocyte ratio (NLR) as an independent risk factor of in-hospital mortality, using the Akaike Information Criterion (AIC). Data were collected from 2109 included patients. We created models using a sample with complete laboratory tests n = 401 and then applied them to the whole studied group excluding patients with missing singular variables. We estimated that albumin may be a better predictor of the COVID-19-severity course compared to NLR, irrespective of comorbidities (p < 0.001). Additionally, we determined that hypoalbuminemia in combination with AST (OR 1.003, p = 0.008) or TBIL (OR 1.657, p = 0.001) creates excellent prediction models for in-hospital mortality. In conclusion, the early evaluation of albumin levels and liver-related parameters may be indispensable tools for the early assessment of the clinical course of patients with COVID-19.

Verified
Journal Article
Open access
PDF file
PRPiotr Rola
Piotr Rola
ADAdrian Doroszko
Adrian Doroszko
Malgorzata TrochaMalgorzata Trocha
Malgorzata Trocha
KGKatarzyna Giniewicz
Katarzyna Giniewicz
KKKrzysztof Kujawa
Krzysztof Kujawa
KMKatarzyna Madziarska
Katarzyna Madziarska
Background: Patients with heart failure represent a vulnerable population for COVID-19 and are prone to having worse prognoses and higher fatality rates. Still, the clinical course of the infection is dynamic, and complication occurrence in particular in patients with heart failure is fairly unpredictable. Considering that individual components of the C2HEST (C2: Coronary Artery Diseases (CAD)/Chronic obstructive pulmonary disease (COPD); H: Hypertension; E: Elderly (Age ≥ 75); S: Systolic HF; T: Thyroid disease) are parallel to COVID-19 mortality risk factors, we evaluate the predictive value of C2HEST score in patients with heart failure (HF) Material and Methods: The retrospective medical data analysis of 2184 COVID-19 patients hospitalized in the University Hospital in Wroclaw between February 2020 and June 2021 was the basis of the study. The measured outcomes included: in-hospital mortality, 3-month and 6-month all-cause-mortality, non-fatal end of hospitalization, and adverse in-hospital clinical events. Results: The heart failure cohort consists of 255 patients, while 1929 patients were assigned to the non-HF cohort. The in-hospital, 3-month, and 6-month mortality rates were highest in the HF cohort high-risk C2HEST stratum, reaching 38.61%, 53.96%, and 65.36%, respectively. In the non-HF cohort, in-hospital, 3-month, and 6-month mortalities were also highest in the high-risk C2HEST stratum and came to 26.39%, 52.78%, and 65.0%, respectively. An additional point in the C2HEST score increased the total death intensity in 10% of HF subjects (HR 1.100, 95% CI 0.968–1.250 p = 0.143) while in the non-HF cohort, the same value increased by 62.3% (HR 1.623, 95% CI 1.518–1.734 p < 0.0001). Conclusions: The C2HEST score risk in the HF cohort failed to show discriminatory performance in terms of mortality and other clinical adverse outcomes during hospitalization. C2HEST score in the non-HF cohort showed significantly better performance in terms of predicting in-hospital and 6-month mortality and other non-fatal clinical outcomes such as cardiovascular events (myocardial injury, acute heart failure, myocardial infarction, cardiogenic shock), pneumonia, sepsis, and acute renal injury.

16 June 2016 in Medycyna Pracy
Verified
Journal Article
Open access
WRWeronika Rymer
Weronika Rymer
AGAndrzej Gładysz
Andrzej Gładysz
HFHenryk Filipowski
Henryk Filipowski
AZAnna Zubkiewicz-Zarębska
Anna Zubkiewicz-Zarębska
ATAnna Tumińska
Anna Tumińska
BKBrygida Knysz
Brygida Knysz
Background: Occupational risk of blood-borne infections is investigated mostly among nurses and doctors, studies concerning non-clinical health personnel (nCHP) being rare. The analysis of the occupational exposure to the hepatitis B virus (HBV) infection and the history of vaccination against...

30 April 2014 in Advances in Clinical and Experimental Medicine
Verified
Journal Article
Open access
LULidia Usnarska-Zubkiewicz
Lidia Usnarska-Zubkiewicz
JHJadwiga Hołojda
Jadwiga Hołojda
MJMichał Jeleń
Michał Jeleń
AZAnna Zubkiewicz-Zarębska
Anna Zubkiewicz-Zarębska
JDJakub Dębski
Jakub Dębski
KKKazimierz Kuliczkowski
Kazimierz Kuliczkowski
The incidence of amyloidosis is difficult to determine because the disease is often undiagnosed or diagnosed incorrectly. In Polish studies, there are no statistics and analyses of the factors that may influence the development of amyloidosis in patients with multiple myeloma. The goal of this study was to estimate the incidence of AL amyloidosis in MM patients in Lower Silesia region. 70 patients treated at the Department of Hematology, Provincial Hospital in Legnica and the Department of Hematology, Blood Neoplasm and Bone Marrow Transplantation, Medical University in Wroclaw were enrolled in the survey. 37 patients were newly diagnosed, 33 had been treated for 2-34 months. The basis for the diagnosis of amyloidosis was the presence of green colored amyloid deposits in the polarized light microscope in the adipose tissue (received from abdominal fold and stained with Congo red). Amyloidosis was diagnosed in 18 (25.7%) patients with MM, 9/9 F /M, aged 47-83 years. 6 (33%) pts with amyloidosis had newly diagnosed MM, in 12 (67%) progression of the disease was diagnosed. Amyloidosis occurred significantly more often (p = 0.048) in already treated patients. The odds ratio (OR) was 2.95. Amyloidosis occurred most frequently in patients with IgG myeloma (67%), (OR = 1.98), was more often found in patients with kappa light chain versus lambda, respectively 67% and 33%. The probability of amyloidosis in patients with clinical stage III was 1.5 times higher (p = 0.05) than in other stages (OR = 1.5), in persons with renal dysfunction was twice as high (OR = 2.4) compared to the renal competence group (p = 0.05). AL amyloidosis in the course of MM occurs in Lower Silesia region with a comparable rate to other regions of the world. It is significantly more often diagnosed in patients with relapsed or refractory disease, in persons with clinical stage III and with renal failure.

3 September 2015 in Polish Archives of Internal Medicine
Verified
Journal Article
Closed access
WRWeronika Rymer
Weronika Rymer
MZMałgorzata Zalewska
Małgorzata Zalewska
ASAleksandra Szymczak
Aleksandra Szymczak
AZAnna Zubkiewicz-Zarębska
Anna Zubkiewicz-Zarębska
BKBrygida Knysz
Brygida Knysz